Perioperative Use of Desmopressin (DDAVP) in Breast Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The propose for this study is to evaluate the safety and tolerability of desmopressin when
administered perioperatively to patients with breast cancer undergoing surgery as first
treatment, and select the optimum dose for the clinical development of the product.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.